TRILEPTAL (oxcarbazepine): Safety Information (Health Canada)
Health Canada Endorsed Important Safety Information on TRILEPTAL (oxcarbazepine): Association of TRILEPTAL (oxcarbazepine) with life-threatening dermatological reactions and multi-organ hypersensitivity In April 2005, Novartis Pharmaceuticals Canada Inc. distributed a letter to Canadian healthcare professionals “concerning the risk of serious dermatological reactions, including Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), as well as multi-organ hypersensitivity reactions in both children and adults, associated with the use of Trileptal (oxcarbazepine).” Revised safety information concerning the risk of Trileptal includes: Life Threatening Dermatological Reactions CLICK HERE to be taken to the advisory page
Health Canada Endorsed Important Safety Information on TRILEPTAL (oxcarbazepine): Association of TRILEPTAL (oxcarbazepine) with life-threatening dermatological reactions and multi-organ hypersensitivity
In April 2005, Novartis Pharmaceuticals Canada Inc. distributed a letter to Canadian healthcare professionals “concerning the risk of serious dermatological reactions, including Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), as well as multi-organ hypersensitivity reactions in both children and adults, associated with the use of Trileptal (oxcarbazepine).”
Revised safety information concerning the risk of Trileptal includes:
Life Threatening Dermatological Reactions
CLICK HERE to be taken to the advisory page
